Clareo Health | Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India
Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent obtained before any study-related activities. (Study-related activities are any procedures that are related to recording of data according to the protocol). The historical data including the data before informed consent obtained (e.g., HbA1c (Glycated Haemoglobin ), FPG (Fasting Plasma Glucose), PPPG (Postprandial Plasma Glucose), severe hypoglycaemia before the start of Ryzodeg™ therapy) can be used for baseline data
Patients with insulin requiring diabetes mellitus and who are scheduled to start treatment with Ryzodeg™ based on the clinical judgment of their treating physician
You may not be if
Known or suspected allergy to Ryzodeg™ any of the active substances or any of the excipients
Previous participation in this study
Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Patients who are or have previously been on Ryzodeg™ therapy
Patients who are participating in other studies or clinical trials
Patients who are pregnant, breast feeding or have the intention of becoming pregnant within the following 12 months
